Evidence map›Paper›PMID 36825196›Full record

ArticleInternational journal of endocrinology2023

CS27109, A Selective Thyroid Hormone Receptor-

Shengjian Huang, Zhou Deng, Wei Wang, Guoqiang Liao, Yiru Zhao, Hua Zhong, Qian Zhang, Jing Liu, Xuhua Mao, Beizhong Chen and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Psoas Muscle Index, Systemic Inflammation, and Liver Fibrosis in MAFLD: A Case-Control Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution.

Shengjian HuangShenzhen Chipscreen Biosciences Co., Ltd., Shenzhen 518052, China.ORCID https://orcid.org/0000-0002-4666-3788
Zhou DengShenzhen Chipscreen Biosciences Co., Ltd., Shenzhen 518052, China.
Wei WangChengdu Chipscreen Pharmaceutical Ltd., Chengdu 610213, China.
Guoqiang LiaoChengdu Chipscreen Pharmaceutical Ltd., Chengdu 610213, China.
Yiru ZhaoChengdu Chipscreen Pharmaceutical Ltd., Chengdu 610213, China.
Hua ZhongChengdu Chipscreen Pharmaceutical Ltd., Chengdu 610213, China.
Qian ZhangChengdu Chipscreen Pharmaceutical Ltd., Chengdu 610213, China.
Jing LiuChengdu Chipscreen Pharmaceutical Ltd., Chengdu 610213, China.
Xuhua MaoChengdu Chipscreen Pharmaceutical Ltd., Chengdu 610213, China.
Beizhong ChenChengdu Chipscreen Pharmaceutical Ltd., Chengdu 610213, China.
Desi PanShenzhen Chipscreen Biosciences Co., Ltd., Shenzhen 518052, China.ORCID https://orcid.org/0000-0002-2104-3902
You ZhouShenzhen Chipscreen Biosciences Co., Ltd., Shenzhen 518052, China.ORCID https://orcid.org/0000-0002-0296-1150
Shenzhen Chipscreen Biosciences Co.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aim: Thyroid hormone receptor- Materials and Methods: We evaluated Results: CS27109 showed pronounced activity and selectivity to THR- Conclusions: CS27109 shows comparative

Identifiers

PMID36825196
PMCPMC9943626
OpenAlexW4320712575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.